If I were shopping for a biotech company with my own money, I would pass on ICPT. The phase-3 REGENERATE trial is laden with pitfalls, IMO (#msg-117301781), and a monotherapy is unlikely to be the answer in a multifaceted disease such as NASH.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.